Genextra S.p.A. 13D/13G Filings for Quince Therapeutics, Inc. (QNCX)

Genextra S.p.A. 13D and 13G filings for Quince Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2025-02-18
1:46 pm
Purchase		 2024-10-18 13G Quince Therapeutics, Inc.
QNCX		 Genextra S.p.A. 2,806,611
6.490%		 280,661increase
(+11.11%)		 Filing
2023-12-14
5:51 pm
Purchase		 2023-10-20 13G Quince Therapeutics, Inc.
QNCX		 Genextra S.p.A. 2,525,950
5.890%		 2,525,950increase
(New Position)		 Filing